FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development

The director of the agency’s patient-focused drug development program talks about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.

PFDD decade
Director of US FDA's patient-focused drug development program talks about its accomplishments and future initiatives • Source: Shutterstock

The pharmaceutical industry and patient advocacy groups have been avidly following the progress of the US Food and Drug Administration’s patient-focused drug development program since its launch 10 years ago. The goal of PFDD is to help ensure that patients’ experiences, perspectives, needs and priorities are incorporated throughout the drug development process and regulatory evaluation.

Under a commitment made in the 2012 reauthorization of the Prescription Drug User Fee Act (PDUFA V), the agency began...

Welcome to In Vivo

Create an account to read this article

More from Leadership

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.